March 2026 Research Update

This month, studies in people with autoimmune pulmonary alveolar proteinosis (aPAP) added a clearer picture of how whole-lung lavage (WLL, a procedure that washes out the lungs) is being used in real-world care, and how outcomes can vary depending on the clinical situation. In one center's experience, WLL was linked with improved breathing and oxygen levels for many patients, while inhaled GM-CSF (a medicine that aims to correct the underlying immune problem in aPAP) had mixed longer-term outcomes. Reports that included patients with active infections highlighted that timing and complexity of illness may be important, but the evidence comes mainly from case reports rather than head-to-head trials. [1] [2]

In a group of 39 people with aPAP followed over time, WLL was reported to improve shortness of breath and oxygenation, and chest imaging often showed the lung changes shrinking after treatment. Some patients needed more than one WLL, showing that aPAP can be an ongoing condition even when a procedure helps. In the same report, inhaled GM-CSF was used in a subset, with variable long-term results and no GM-CSF-related side effects reported in that cohort. [1]

A separate report focused on aPAP complicated by opportunistic infection, alongside a review of 27 published cases where people with PAP had infections around the time of WLL. Across those published reports, most cases described improvement after WLL when it was done after infection control, while a death was reported in a case where WLL happened during active infection; the index case in the new report also had a fatal outcome despite delaying WLL until infection control was pursued. Because these are case-based reports with uneven details, they do not prove what timing is best, but they do underline that infection makes WLL decisions more complicated and outcomes less predictable. [2]

For patients and caregivers, this month mainly adds understanding of what has been reported in routine care and in complex, high-risk situations, rather than delivering a new standard approach. The strongest signal across these reports is that WLL is commonly used and is often followed by symptom and oxygen improvement in aPAP, but repeated procedures may be needed and results can differ between people. When serious infection is present, the available evidence is mostly case reports, so it cannot give a firm rule, but it does clarify why teams often try to address infection before WLL and why outcomes can still be poor in some very ill patients. [1] [2]

Two studies looked at ways to recognize pulmonary alveolar proteinosis (PAP) more accurately, especially when it can resemble other lung problems. One study suggested that computer-based analysis of CT scans might help tell nodular PAP apart from early lung cancer. Another small report suggested a laboratory stain on bronchoalveolar lavage fluid (fluid collected during a lung wash test) could support a PAP diagnosis when other specialized tools are not available. [3] [4]

For nodular PAP, a retrospective study compared 16 people with nodular PAP to 52 people with early-stage lung adenocarcinoma and built prediction models. The CT-based model separated the two groups fairly well, and adding simple clinical or blood information produced a numerically higher accuracy measure, although the two models performed similarly overall. The study also noted group differences such as nodular PAP patients being younger and having lower LDH (a blood enzyme that can rise with tissue stress) than the lung cancer group, although the study did not include common PAP-specific testing like GM-CSF autoantibodies. [3]

In a small case-based report, two PAP cases with sufficient bronchoalveolar lavage samples showed strong positivity for Napsin-A in the protein-rich "globules" seen on cytology. The authors suggested that this stain could potentially help confirm PAP in the laboratory. Because only two PAP samples were usable for the test, this is an early signal rather than a confirmed diagnostic standard. [4]

For patients, these studies are mainly about reducing diagnostic uncertainty, especially when imaging or lavage findings could be mistaken for something else. The CT-model work is still research and needs validation in other hospitals, so it is not yet a routine test, but it clarifies that nodular PAP can be difficult to distinguish from early lung cancer and that imaging patterns can be quantified to help. The Napsin-A report is also early-stage, but it suggests a potentially practical lab tool that could be helpful when more specialized PAP testing is not available. [3] [4]

This month included case reports showing that PAP can appear as a secondary problem alongside other serious heart or immune-system conditions, and may be recognized only when the overall illness becomes very complicated. In these reports, PAP was not the only diagnosis, and it was described as potentially adding to low oxygen levels and making the overall course harder to manage. These cases do not tell us how often this happens, but they make the possibility more concrete for people with unusual or disproportionate breathing problems. [5] [6]

One case described a man with a large atrial septal defect and severe pulmonary arterial hypertension who underwent surgical closure and then developed profound instability after surgery; lung tissue later showed secondary PAP. The report suggested PAP may have contributed to difficult-to-correct low oxygen levels and to pulmonary hypertension that did not respond as expected. This is a single case and cannot predict outcomes for others, but it illustrates how PAP can be missed when other major heart-lung problems are present. [5]

Another case described a man who developed pleuroparenchymal fibroelastosis (a scarring condition affecting the lung edges) with secondary PAP after a stem cell transplant. Testing did not show anti-GM-CSF antibodies, supporting a non-autoimmune, secondary form, and the report discussed immune dysregulation and chronic graft-versus-host disease as possible contributors. Despite multiple treatments, the lung disease progressed and the patient died during a SARS-CoV-2-associated acute worsening, highlighting how severe and overlapping lung conditions can be in some transplant settings. [6]

For patients and caregivers, these reports mainly help clarify that PAP is not always a stand-alone disease and can occur secondary to other conditions, including complex heart disease or post-transplant immune problems. The evidence is limited to individual cases, so it does not change what is expected for most people with PAP, but it does explain why diagnosis can be delayed when other major illnesses dominate the picture. What remains uncertain is how common these secondary forms are in similar patient groups and which tests best identify them early, since the reports describe discovery during extensive evaluation rather than a clear screening approach. [5] [6]

One study this month focused on ABCA3 deficiency, a genetic cause of childhood interstitial lung disease that affects surfactant handling in the lungs, which is biologically related to the broader area of surfactant disorders. In a Japanese national survey, ABCA3 deficiency was identified much less often than reported in several other regions. The study also showed that the age when symptoms begin can matter, with worse outcomes reported for those who became ill at birth than for those with later onset. [7]

Among 291 children evaluated for interstitial lung disease, 11 had ABCA3 deficiency, including one sibling pair, and there was a wide variety of disease-causing genetic variants rather than a single common mutation. Most cases had two different ABCA3 variants inherited as a pair, but in two children the diagnosis was supported by lung pathology even though only one pathogenic variant was detected. The incidence in this Japanese cohort was reported as lower than in the United States, Europe, and Argentina, emphasizing that genetic patterns can vary by population. [7]

For PAP patients, this study does not directly change PAP diagnosis or treatment because it is about a different condition, but it adds context about diseases where surfactant processing goes wrong. For families dealing with childhood interstitial lung disease, it clarifies that ABCA3 deficiency may be less common in Japan than in some other regions and that outcomes in reported cases differed by when disease started. It also leaves uncertainty about why incidence differs by region and how often standard genetic testing misses a second variant when pathology strongly suggests ABCA3 deficiency. [7]